In April, Morgon drove a couple of hours from his home in Lausanne, Switzerland, to a pharmacy in Lyon, France, for an Astra shot. A small trial in Germany suggested that mixing Astra and Pfizer shots could trigger antibody responses almost four times higher than a two-dose course of the Pfizer vaccine. Researchers are also looking at mixing Astra’s shot with the Sputnik V vaccine among trial participants in Russia, Azerbaijan, Belarus and the United Arab Emirates. That didn’t stop Bill Enright, the Maryland-based CEO of Vaccitech, the British firm that designed the technology behind AstraZeneca’s shot. Because the Astra shot isn’t yet approved in the U.S., Enright got Johnson & Johnson’s vaccine, which uses similar technology but is intended for a one-dose regimen.

Source: The Edge Markets June 11, 2021 05:03 UTC